Technical Analysis for CRBU - Caribou Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.03 | 3.32% | 0.07 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 3.32% | |
| Wide Bands | Range Expansion | 3.32% | |
| Oversold Stochastic | Weakness | 3.32% | |
| Bullish Engulfing | Bullish | 1.76% | |
| NR7 | Range Contraction | 1.76% | |
| Wide Bands | Range Expansion | 1.76% | |
| Oversold Stochastic | Weakness | 1.76% | |
| 50 DMA Resistance | Bearish | 2.27% | |
| Doji - Bullish? | Reversal | 2.27% | |
| Stochastic Reached Oversold | Weakness | 2.27% |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Caribou Biosciences, Inc. Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.33 |
| 52 Week Low | 1.5 |
| Average Volume | 1,212,842 |
| 200-Day Moving Average | 3.21 |
| 50-Day Moving Average | 2.05 |
| 20-Day Moving Average | 2.20 |
| 10-Day Moving Average | 2.28 |
| Average True Range | 0.21 |
| RSI (14) | 42.53 |
| ADX | 21.33 |
| +DI | 21.80 |
| -DI | 20.50 |
| Chandelier Exit (Long, 3 ATRs) | 2.36 |
| Chandelier Exit (Short, 3 ATRs) | 2.41 |
| Upper Bollinger Bands | 2.86 |
| Lower Bollinger Band | 1.54 |
| Percent B (%b) | 0.32 |
| BandWidth | 60.43 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.08 |
| MACD Histogram | -0.0663 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.22 | ||||
| Resistance 3 (R3) | 2.23 | 2.15 | 2.17 | ||
| Resistance 2 (R2) | 2.15 | 2.09 | 2.15 | 2.16 | |
| Resistance 1 (R1) | 2.06 | 2.05 | 2.02 | 2.05 | 2.14 |
| Pivot Point | 1.98 | 1.98 | 1.97 | 1.98 | 1.98 |
| Support 1 (S1) | 1.89 | 1.92 | 1.85 | 1.88 | 1.78 |
| Support 2 (S2) | 1.81 | 1.88 | 1.81 | 1.76 | |
| Support 3 (S3) | 1.72 | 1.81 | 1.75 | ||
| Support 4 (S4) | 1.71 |
